Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 7,459 matching trials from the live ClinicalTrials.gov search.

Filters: Denver, Colorado Clear all

Conditions: Disease, Hodgkin
Interventions: brentuximab vedotin, placebo; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 32
States / cities: Duarte, California • San Francisco, California • Stanford, California + 26 more

Conditions: Kidney Failure, Acute, Renal Insufficiency
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: Not listed
Enrollment: 1,550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 6
States / cities: Denver, Colorado • Danbury, Connecticut • New Haven, Connecticut + 3 more

Conditions: Non-relapsing Secondary Progressive Multiple Sclerosis
Interventions: Tolebrutinib, Placebo to match Tolebrutinib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 1,131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 51
States / cities: Birmingham, Alabama • Phoenix, Arizona • Arcadia, California + 44 more

Conditions: Hot Flashes
Interventions: Brisdelle (paroxetine mesylate), Placebo capsules; Drug
Lead sponsor: Noven Therapeutics; Industry
Eligibility: 40 Years and older · Female only
Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 32
States / cities: Montgomery, Alabama • Chandler, Arizona • San Diego, California + 28 more

Conditions: Non Small Cell Lung Cancer (NSCLC)
Interventions: Dacomitinib, Doxycycline, Probiotic, Alclometasone cream; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 79
States / cities: Duarte, California • Fullerton, California • Irvine, California + 49 more

Conditions: Frail Older Adults
Interventions: Progressive Multi-Component Intervention, Usual Care; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 65 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 2
States / cities: Aurora, Colorado • Glenside, Pennsylvania

Conditions: Fetal Growth Restriction
Interventions: Left lateral recumbent positioning; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Aurora, Colorado • Denver, Colorado

Conditions: Chronic Kidney Diseases, Pruritus
Interventions: CR845 0.25 mg Oral Tablet, CR845 0.5 mg Oral Tablet, CR845 1 mg Oral Tablet, Placebo Oral Tablet; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 60
States / cities: Birmingham, Alabama • Florence, Alabama • Phoenix, Arizona + 52 more

Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies, Myelodysplastic Syndromes
Interventions: AG-120; Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 18 Years and older
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 21 more

Conditions: Healthy Adult Participants
Interventions: Not listed
Lead sponsor: Ecotera Health LLC; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 51
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 48 more

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Daratumumab/rHuPH20; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 75 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2040
U.S. locations: 837
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 526 more

Conditions: Chronic Idiopathic Constipation (CIC)
Interventions: Tenapanor 5 mg BID, Tenapanor 25 mg BID, Tenapanor 50 mg BID, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 692 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 109
States / cities: Foley, Alabama • Saraland, Alabama • Chandler, Arizona + 98 more

Conditions: Stress Urinary Incontinence
Interventions: Altis Single Incision Sling, Transobturator or Retropubic Sling; Device
Lead sponsor: Coloplast A/S; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 26
States / cities: Stanford, California • Denver, Colorado • Hialeah, Florida + 23 more

Conditions: Trachebronchomalacia (TBM), Hyper Dynamic Airway Collapse (HDAC), Obstructive Sleep Apnea (OSA)
Interventions: Not listed
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Asthma
Interventions: Indacaterol, Salmeterol, Placebo to Indacaterol, Placebo to Salmeterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 71
States / cities: Glendale, Arizona • Scottsdale, Arizona • Encinitas, California + 64 more

Conditions: Psoriatic Arthritis
Interventions: Adalimumab, Upadacitinib, Placebo to Upadacitinib, Placebo to Adalimumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 1,705 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 114
States / cities: Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 100 more

Conditions: Influenza
Interventions: Baloxavir Marboxil, Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years and older
Enrollment: 363 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 14
States / cities: Torrance, California • Denver, Colorado • Decatur, Georgia + 11 more

Conditions: Ankle Sprains
Interventions: MRX-7EAT, Placebo, Lidocaine, Etodolac; Drug
Lead sponsor: MEDRx USA, Inc.; Industry
Eligibility: 14 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 33
States / cities: Phoenix, Arizona • North Little Rock, Arkansas • Chico, California + 30 more

Conditions: Stress Urinary Incontinence
Interventions: Duloxetine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
Interventions: HC-1119, Enzalutamide; Drug
Lead sponsor: Hinova Pharmaceuticals USA, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Denver, Colorado • Washington D.C., District of Columbia • Jeffersonville, Indiana + 5 more

Conditions: Pancreatic Cancer
Interventions: exatecan mesylate, gemcitabine hydrochloride; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 66
States / cities: Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 59 more

Conditions: Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm
Interventions: Best Practice, Biospecimen Collection, Bone Metastases Treatment, Computed Tomography, Conventional Radiotherapy, Magnetic Resonance Imaging, Patient Observation, Questionnaire Administration, Stereotactic Body Radiation Therapy; Other · Procedure · Radiation
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 624
States / cities: Fairbanks, Alaska • Gilbert, Arizona • Phoenix, Arizona + 450 more

Conditions: Urothelial Cancer
Interventions: Iza-bren, Cisplatin, Gemcitabine, Carboplatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 35
States / cities: Gilbert, Arizona • Fullerton, California • Palo Alto, California + 26 more

Conditions: Primary Mediastinal Large B-Cell Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, Filgrastim, Lumbar Puncture, Nivolumab, Pegfilgrastim, Positron Emission Tomography, Prednisolone, Prednisone, Radiation Therapy, Rituximab, Rituximab and Hyaluronidase Human, Vincristine Sulfate; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 215
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 162 more

Search by objective public record fields.

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Examining New Diagnostic Tests for Acute Kidney Injury After Heart Surgery

Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

Improving Function, Participation and Function After Acute Hospitalization in Older Adults

Maternal Left Lateral Position in Fetal Growth Restriction

A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Observational Study of Decentralized Urine Optical Interaction Patterns Associated With Environmental Microplastic and Nanoplastic Exposure

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults

Altis® 522 Trial - Treatment of Female Stress Urinary Incontinence

Correlation Between Trachebroncho Malacia/Hyperdynamic Airway Collapse And Obstructive Sleep Apnea

Efficacy and Safety of Different Doses of Indacaterol

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza

MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Ankle Sprains

To Evaluate the Safety of Duloxetine in Patients With Stress Urinary Incontinence

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma